Prognostic Value of Circulating Endothelial Cells in Glioblastoma Patients: a Pilot Study

Figures & data

Table 1. Patient characteristics.

Characteristics	Patients (n = 22)
Age, years (average)	63
Median age (range)	42–81
Sex
Male	63.6%
Female	36.4%
ECOG (diagnosis)
0	27.3%
1	68.2%
ECOG post-surgery
0	22.7%
1	72.7%
3	4.5%
Location
1 – frontal	9 (41%)
2 – temporal	9 (41%)
3 – parietal	2 (10%)
4 – occipital	1 (4%)
5 – others	1 (4%)
Extent of surgery
Biopsy	18%
Partial and subtotal resection	32%
Complete resection	50%

Figure 1. Overall survival and circulating endothelial cells.

The median overall survival was 17.4 months for patients in group 1 and 8.12 months for patients in group 2 (p = <0.001). n = 10, group 1; n = 5, group 2.

OS: Overall survival.

Figure 2. Progression-free survival and circulating endothelial cells.

The median progression free survival was 8.94 months for group 1 and 3.95 months for group 2 (p = 0.097). n = 17, group 1; n = 5, group 2.

CEC: circulating endothelial cell.

Figure 3. Circulating endothelial cell count before and after surgery and radiotherapy.

There was a non-significant increase in CEC count after surgery and radiotherapy, n = 5.

CEC: circulating endothelial cell.

Figure 4. Overall survival and extent of surgery.

Median overall survival depending on the extent of surgery was 25.33 months (IC 95%: 5.54–45.12) for complete and subtotal resection and 8.23 months (IC 95%: 0.0–17.75) for partial resection or biopsy only (IC), p = 0.014. n = 16, complete/subtotal resection; n = 6, partial resection/biopsy.

Figure 5. Overall survival and adjuvant temozolomide.

Median overall survival depending on treatment with adjuvant temozolomide was 6.936 months for no adjuvant temozolomide or 17.42 months for adjuvant temozolomide (p ≤ 0.001). n = 6, only radiotherapy; n = 15, adjuvant temozolomide.

OS: Overall survival.